Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial.

[1]  D. Chan,et al.  Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. , 1998, The Journal of urology.

[2]  D. Woodrum,et al.  Two-year stability of free and total PSA in frozen serum samples. , 1998, Urology.

[3]  A W Partin,et al.  Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. , 1998, JAMA.

[4]  P. Humphrey,et al.  Percentage of free serum prostate-specific antigen as a predictor of pathologic features of prostate cancer in a screening population. , 1998, Urology.

[5]  J. Pannek,et al.  The use of percent free prostate specific antigen for staging clinically localized prostate cancer. , 1998, The Journal of urology.

[6]  C. Ed,et al.  Bicalutamide-associated fulminant hepatic failure. , 1997 .

[7]  J. Shaffer,et al.  Analytical performance of the Tandem-R free PSA immunoassay measuring free prostate-specific antigen. , 1997, Clinical chemistry.

[8]  A W Partin,et al.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.

[9]  E. Metter,et al.  Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. , 1997, Urology.

[10]  B. G. Blijenberg,et al.  The free-to-total serum prostate specific antigen ratio for staging prostate carcinoma. , 1997, The Journal of urology.

[11]  L. Shamel,et al.  Stability of free prostate-specific antigen in serum samples under a variety of sample collection and sample storage conditions. , 1996, Urology.

[12]  J. Pannek,et al.  The role of free/total prostate-specific antigen ratio in the prediction of final pathologic stage for men with clinically localized prostate cancer. , 1996, Urology.

[13]  A W Partin,et al.  Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. , 1996, Urology.

[14]  L. Baert,et al.  Free-to-total prostate specific antigen ratio as a single test for detection of significant stage T1c prostate cancer. , 1996, The Journal of urology.

[15]  J. Oesterling,et al.  Free, complexed, and total serum prostate-specific antigen concentrations and their proportions in predicting stage, grade, and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate. , 1996, Urology.

[16]  S. Loening,et al.  Analytical performance and clinical validity of two free prostate-specific antigen assays compared. , 1996, Clinical chemistry.

[17]  C. Cuny,et al.  Using proportions of free to total prostate-specific antigen, age, and total prostate-specific antigen to predict the probability of prostate cancer. , 1996, Urology.

[18]  W. Catalona,et al.  Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. , 1995, JAMA.

[19]  M. Brawer,et al.  Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. , 1995, Urology.

[20]  W. Catalona,et al.  Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. , 1994, The Journal of urology.

[21]  P. Walsh,et al.  Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. , 1994, JAMA.

[22]  O. Nilsson,et al.  Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. , 1993, The Journal of urology.

[23]  D. Hosmer,et al.  Applied Logistic Regression , 1991 .

[24]  O. Nilsson,et al.  Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. , 1991, Clinical chemistry.

[25]  H. Lilja,et al.  Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. , 1990, European journal of biochemistry.

[26]  W. Catalona,et al.  Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. , 1998, The Journal of urology.

[27]  Taylor Murray,et al.  Cancer statistics, 1998 , 1998, CA: a cancer journal for clinicians.

[28]  B. Tombal,et al.  Free to total prostate‐specific antigen (PSA) ratio is superior to total‐PSA in differentiating benign prostate hypertrophy from prostate cancer , 1996, The Prostate. Supplement.

[29]  F. Schröder,et al.  The TNM classification of prostate cancer , 1992, The Prostate. Supplement.

[30]  U. Stenman,et al.  A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. , 1991, Cancer research.

[31]  N. Bolton,et al.  Nuclear androgen receptors in the epithelium and stroma of human benign prostatic hypertrophic glands , 1983, The Prostate.